Latest news

• AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris

  AstraZeneca and Alexion are in the process of developing Ultomiris for generalised myasthaenia gravis and neuromyelitis optica spectrum disorder, while also working to produce a new subcutaneous formulation of the medicine

• New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses

  The new data demonstrates Enspryng’s longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare debilitating disease that affects the central nervous system.

• Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

  Currently, Viela has one US Food and Drug Administration (FDA) approved asset – Uplizna (inebilizumab-cdon), which is indicated for the treatment of the rare condition neuromyelitis optica spectrum disorder (NMOSD). ... Viela is also evaluating Uplizna

• Roche’s Soliris rival Enspryng bags FDA approval

  Roche’s neuromyelitis optica spectrum disorder (NMOSD) drug Enspryng has scored US Food and Drug Administration (FDA) approval, setting up a market clash with Alexion’s Soliris. ... Enspryng ( satralizumab) has been approved to treat adult patients

• Roche’s Soliris rival satralizumab scores in phase 3 study

  Roche has new positive data for its IL-6 targeting antibody satralizumab for neuromyelitis optica spectrum disorder (NMOSD), with regulatory decisions expected in 2020 as it prepares to go